KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Preferred Stock Liabilities (2012 - 2015)

Gilead Sciences posted quarterly Preferred Stock Liabilities of $2.0 million for Q4 2015, down 86.67% year-on-year from $15.0 million in Q4 2014, and down 50.0% on a QoQ basis from $4.0 million in Q3 2015.

Gilead Sciences (GILD) has 4 years of Preferred Stock Liabilities data on file, last reported at $2.0 million in Q4 2015.

  • For the quarter ending Q4 2015, Preferred Stock Liabilities fell 86.67% year-over-year to $2.0 million; the trailing twelve-month figure through Dec 2015 stood at $2.0 million (down 86.67% YoY), and the FY2015 full-year result was $2.0 million, down 86.67% from the prior year.
  • Preferred Stock Liabilities for Q4 2015 stood at $2.0 million, down from $4.0 million in the prior quarter.
  • Across five years, Preferred Stock Liabilities topped out at $64.0 million in Q4 2013 and bottomed at $2.0 million in Q4 2015.
  • The 4-year median for Preferred Stock Liabilities is $13.0 million (2014), against an average of $21.9 million.
  • The widest annual swing landed in 2013, when Preferred Stock Liabilities surged 795.48%; it then tumbled 86.67% in 2015.
  • A 4-year view of Preferred Stock Liabilities shows it stood at $7.1 million in 2012, then surged by 795.48% to $64.0 million in 2013, then plunged by 76.56% to $15.0 million in 2014, then sank by 86.67% to $2.0 million in 2015.
  • The last three Preferred Stock Liabilities figures came in at $2.0 million (Q4 2015), $4.0 million (Q3 2015), and $7.0 million (Q2 2015), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn -
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn -
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn -
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn -
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn -
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn -
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn -
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn -
10 Gsk 88.34 Bn 83.66 Bn - -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2015 2.00 Mn
Sep 30, 2015 4.00 Mn
Jun 30, 2015 7.00 Mn
Mar 31, 2015 11.00 Mn
Dec 31, 2014 15.00 Mn
Sep 30, 2014 27.38 Mn
Jun 30, 2014 35.88 Mn
Mar 31, 2014 45.77 Mn
Dec 31, 2013 64.00 Mn
Dec 31, 2012 7.15 Mn